COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,845 Articles (22,553 medRxiv, 8,292 bioRxiv)

Most recent first Previous |  Page 1427: Articles 14261-14270  | Next

Safety and efficacy of antiviral therapy alone or in combination in COVID-19 - a randomized controlled trial (SEV COVID Trial)
SEV COVID trial group, , Panda, P. K.
10.1101/2021.06.06.21258091 — Posted: 2021-06-08
Drug Repurposing of potential drug targets for treatment of COVID-19
Gupta, R., Nwachuku, E., Zusman, B., Jha, R., Puccio, A.
10.1101/2021.06.02.21258223 — Posted: 2021-06-08
Intronic regulation of SARS-CoV-2 receptor (ACE2) expression mediated by immune signaling and oxidative stress pathways
Richard, D., Muthuirulan, P., Aguiar, J., Doxey, A., Banerjee, A., Mossman, K., Hirota, J., Capellini, T. D.
10.1101/2021.06.07.447351 — Posted: 2021-06-07
Dual roles of a novel oncolytic viral vector-based SARS-CoV-2 vaccine: preventing COVID-19 and treating tumor progression
Caligiuri, M. A., Yu, J., Sun, Y., Dong, W., Tian, L., Rao, Y., Qin, C., Jaramillo, S. A., Settles, E. W., Ma, S., Zhang, J., Yu, K., Xu, B., Yan, J., Ma, R., Li, Z., Dadwal, S. S., Barker, B. M., Keim, P. S., Feng, P.
10.1101/2021.06.07.447286 — Posted: 2021-06-07
Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome
Chen, Y.-S., Lu, S., Zhang, B., Du, T., Li, W.-J., Lei, M., Zhou, Y., Zhang, Y., Liu, P., Sun, Y.-Q., Zhao, Y.-L., Yang, Y., Peng, X., Yang, Y.-G.
10.1101/2021.06.06.447293 — Posted: 2021-06-07
Hot water extract of Arthrospira maxima (AHWE) has broad-spectrum antiviral activity against RNA virus including coronavirus SARS-CoV2, and the antivirus spray application
Chen, Y.-H., Liao, Y.-C., Huang, J. Y., Kung, Y.-A., Chiueh, C.-C.
10.1101/2021.06.06.446935 — Posted: 2021-06-07
The local anaesthetic procaine prodrugs ProcCluster(R) and Procaine-hydrochloride impair SARS-CoV-2 replication in vitro
Häring, C., Schroeder, J., Loeffler, B., Engert, B., Ehrhardt, C.
10.1101/2021.06.07.447335 — Posted: 2021-06-07
B.1.1.7 and B.1.351 variants are highly virulent in K18-ACE2 transgenic mice and show different pathogenic patterns from early SARS-CoV-2 strains
Radvak, P., Kwon, H. J., Kosikova, M., Ortega-Rodriguez, U., Xiang, R., Phue, J.-N., Shen, R.-F., Rozzelle, J., Kapoor, N., Rabara, T., Fairman, J., Xie, H.
10.1101/2021.06.05.447221 — Posted: 2021-06-07
Evolutionary velocity with protein language models
Hie, B. L., Yang, K. K., Kim, P. S.
10.1101/2021.06.07.447389 — Posted: 2021-06-07
E156/G and Arg158, Phe-157/del mutation in NTD of spike protein in B.1.167.2 lineage of SARS-CoV-2 leads to immune evasion through antibody escape
Chaudhari, A., Kumar, D., Joshi, D. M., Patel, A., joshi, P. C.
10.1101/2021.06.07.447321 — Posted: 2021-06-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).